DGX stock: buy or sell?

DGX stock price: $101.60 -0.99% At close on August 23rd, 2019

Updated on:
August 23rd, 2019


Quest Diagnostics slightly fell a lame -0.99% and closed at $101.60.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.

Should I buy DGX stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Quest Diagnostics stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean DGX will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Quest Diagnostics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 15 ratings published for DGX stock in the last month.

Is DGX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-8Evercore ISIn/aBuy
2019-8-23Morgan Stanleyn/aOverweight
2019-7-24Morgan Stanleyn/aOverweight
2019-7-24JPMorgan Chase & Co.n/aNeutral
2019-7-24Credit Suisse Groupn/aNeutral
2019-7-24Canaccord Genuityn/aBuy
2019-7-15Goldman Sachs GroupNeutralSell
2019-4-25Morgan StanleyOverweightOverweight
2019-4-24UBS Groupn/aNeutral
2019-4-2Wolfe Researchn/aUnderperform
2019-4-2Jefferies Financial GroupHoldBuy
2019-3-18Credit Suisse GroupOutperformNeutral
2019-2-19Credit Suisse GroupOutperformOutperform

DGX stock analysis

Daily outlook

Shares of Quest Diagnostics ended today at $101.60 and slightly fell a lame -0.99%.

Shares of Quest Diagnostics closed today at $101.60 and slightly fell a lame -0.99%. Since June when SMA100d and SMA200d crossed up, DGX price gained $1.09 per share (1.08%). DGX is soaring again after a 2.90% correction from its last top on August 13th at $102.19. Since price and SMA200d lines crossed up on April, DGX climbed $7.84 (8.36%).

DGX stock chart (daily)

Weekly outlook

Shares of Quest Diagnostics stepped up a slightly good 0.99% this week.

DGX shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $96.94 early August. Previous top ($104.90) will play as a resistance in possible new gains. Since mid June when SMA20w and SMA40w crossed up, DGX price gained $2.77 per share (2.80%). Since price and SMA40w lines crossed up late April, DGX climbed $16.29 (19.10%).

DGX stock chart (weekly)

DGX stock price history

DGX stock went public on December 17th, 1996 with a price of $2.981. Since then, DGX stock surged a 3,309.40%, with a yearly average of 150.40%. If you had invested $1,000 in DGX stock in 1996, it would worth $33,094.00 today.

1: Adjusted price after possible price splits or reverse-splits.

DGX stock historical price chart

DGX stock reached 52-week highs at $108.56, and all-time highs 2018-06-25 with a price of 112.74.

DGX stock price target is $104.90

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We have 13 price targets for Quest Diagnostics stock released in the last month:
DGX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-8Evercore ISIReiteratesn/a$108.00-
2019-8-23Morgan StanleyRaises Target$111.00$121.009%
2019-7-24Morgan StanleyRaises Target$104.00$111.006.7%
2019-7-24JPMorgan Chase & Co.Raises Target$100.00$111.0011%
2019-7-24Credit Suisse GroupReiterates$99.00$105.006.1%
2019-7-24Canaccord GenuityRaises Target$108.00$112.003.7%
2019-7-15Goldman Sachs GroupDowngrades$90.00$85.00-5.6%
2019-4-25Morgan StanleyRaises Target$98.00$104.006.1%
2019-4-24UBS GroupRaises Target$91.00$99.008.8%
2019-4-24CitigroupRaises Target$93.00$102.009.7%
2019-3-18Credit Suisse GroupDowngradesn/a$91.00-
2019-2-19Credit Suisse GroupLowers Target$103.00$101.00-1.9%
(in average)$99.70$104.905.0%
Moving in a range from $121.00 and $85.00, the price forecast for DGX stock is $104.90. In average, analysts' outlook on DGX price target is positive, increasing the target by a 5.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Quest Diagnostics presented its financial report, in line with analysts' consensus and posted a $1.36 Earnings per Share. Unfortunately, reported EPS is not yet available in our database.
DGX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Quest Diagnostics annual turnover grew a tiny 1.74% to $7,531.00 million USD from $7,402.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) remained constant a -0.66% to 9.77%.

DGX annual Sales and Income evolution
2013$7,150 M-$811 M11.3%-
2014$7,435 M3.99%$556 M7.5%-31.44%
2015$7,493 M0.78%$709 M9.5%27.52%
2016$7,515 M0.29%$645 M8.6%-9.03%
2017$7,402 M-1.50%$772 M10.4%19.69%
2018$7,531 M1.74%$736 M9.8%-4.66%

Quarterly financial results

Quest Diagnostics posted $1,839.00 M in sales for 2018-Q4, a -2.65% less compared to previous quarter. Reported quarter income marked $127.00 M with a profit margin of 6.91%. Profit margin depreciated a -4.37% compared to previous quarter when profit margin was 11.28%. When comparing revenues to same quarter last year, Quest Diagnostics sales marked a frightening slide and plummed a -15.33%. Looking back to recent quarterly results, Quest Diagnostics posted 2 positive quarters in a row.
DGX quarterly Sales and Income evolution
2017-Q2$1,940 M-$193 M9.9%-
2017-Q3$1,930 M-0.52%$160 M8.3%-17.10%
2017-Q4$2,172 M12.54%$254 M11.7%58.75%
2018-Q1$1,884 M-13.26%$177 M9.4%-30.31%
2018-Q2$1,919 M1.86%$219 M11.4%23.73%
2018-Q3$1,889 M-1.56%$213 M11.3%-2.74%
2018-Q4$1,839 M-2.65%$127 M6.9%-40.38%
2019-Q1$1,891 M2.83%$164 M8.7%29.13%

Quest Diagnostics ownership

When you are planning to buy a stock, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Quest Diagnostics, 0.35% of all outstanding shares are owned by its staff.

Bearish positions for DGX stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Quest Diagnostics:

Market cap$13.7 B$148.3 M$2.7 B$16.3 B$2.3 B
Total shares134.6 M47.2 M37.1 M98.5 M95.3 M
Float shares134.0 M35.2 M25.0 M97.1 M94.8 M
  - Institutional holdings (%)91.5%75.8%86.9%94.1%77.2%
  - Insider holdings (%)0.4%7.4%2.8%0.6%8.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

DGX summary

Friday, August 23rd, 2019
Day range$101.23 - $103.67
Previous close$102.62
Session gain-0.99%
Average true range$1.72
50d mov avg$101.25
100d mov avg$97.99
200d mov avg$92.24
Daily patternlb01a
Weekly pattern lb03a

Quest Diagnostics performance

To better understand Quest Diagnostics performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Quest Diagnostics performance to Enzo Biochem, Genomic Health, Laboratory Corporation of America, NeoGenomics, Psychemedics and Qiagen:
DGXQuest Diagnostics4.16%17.00%-5.44%
ENZEnzo Biochem-2.79%-10.54%-28.96%
GHDXGenomic Health35.97%-9.76%27.46%
LHLaboratory Corpor...-0.55%11.51%-5.05%

Quest Diagnostics competitors

We selected a few stocks to conform a list of Quest Diagnostics competitors to check if you are interested in investing in DGX:

Latest DGX stock news